EUVIMEDEUVIMED entdecken
Randomisierte kontrollierte StudieVergleichsstudie

Diltiazem reduces levels of NT-proBNP and improves symptoms compared with metoprolol in patients with permanent atrial fibrillation

Katrine Enge iD, Arnljot Tveit iD, Steve Enger iD, Sophia Onarheim, Are Hugo Pripp iD, Peter Selmer Rønningen iD, Magnar Gangås Solberg iD, Rune Byrkjeland iD, Kristoffer Andresen iD, Anders Halsen iD, Hanne Aaserud Aulie iD, Trude Steinsvik iD und 2 weitere

European Heart Journal - Cardiovascular Pharmacotherapy · 2024

DOI: 10.1093/ehjcvp/pvae032 ↗

Kurz gefasst

Randomisierte kontrollierte Studie in der Zeitschrift European Heart Journal - Cardiovascular Pharmacotherapy, 2024. Verfasst von Katrine Enge und 13 weiteren Autor:innen. Beteiligte Einrichtung: Department of Medical Research, Bærum Hospital, Vestre Viken Hospital Trust, Sogneprest Munthe-kaas vei 100, 1346 Gjettum, Norway. Hauptthemen laut MEDLINE: Atrial Fibrillation, Diltiazem, Natriuretic Peptide, Brain, Metoprolol. Die Arbeit wurde bisher 6-mal zitiert (Crossref) und nennt 36 Literaturangaben. Gefördert von: Southern and Eastern Norway Regional Health Authority, Vestre Viken Hospital Trust.

AbstractSchlagwörterBibliografische AngabenZitierenVerwandte Studien

Abstract (Originalsprache)

Aims

Short-term treatment with calcium channel blockers lowers levels of N-terminal pro B-type natriuretic peptide (NT-proBNP) and reduces rhythm-related symptoms compared to treatment with beta-blockers. The aim of this study was to compare the effects of metoprolol and diltiazem for rate control in patients with permanent atrial fibrillation (AF) after 6 months. Methods and results Men and women with permanent AF and preserved left ventricular systolic function were randomized to receive either diltiazem 360 mg or metoprolol 100 mg once daily. The primary endpoint was the level of NT-proBNP after a 6-month treatment period. Secondary endpoints included heart rate, rhythm-related symptoms and exercise capacity. A total of 93 patients (mean age 71 ± 7 years, 28 women) were randomized. After 6-months’ treatment, mean levels of NT-proBNP decreased in the diltiazem group and increased in the metoprolol group, with a significant between-group difference (409.8 pg/mL, 95% CI: 230.6–589.1, P < 0.001). Treatment with diltiazem significantly reduced rhythm-related symptoms compared to baseline, but no change was observed in the metoprolol group. Diltiazem and metoprolol had similar effects on heart rate and exercise capacity.

Conclusion

Diltiazem reduced NT-proBNP levels and improved rhythm-related symptoms. Metoprolol increased peptide levels but had no impact on symptoms despite similar heart rate reduction. Non-dihydropyridine calcium channel blockers should be considered more often for rate control in permanent AF.

Schlagwörter

MeSH-Schlagwörter (MEDLINE)

Atrial FibrillationDiltiazemNatriuretic Peptide, BrainMetoprololPeptide FragmentsCalcium Channel BlockersHeart RateHumansFemaleMaleAgedTreatment OutcomeBiomarkersMiddle AgedAnti-Arrhythmia Agents

Stichwörter der Autor:innen

Atrial fibrillationBeta-blockersCalcium channel blockersNatriuretic peptidesRate controlRhythm-related symptoms

Substanzen

DiltiazemNatriuretic Peptide, BrainMetoprololpro-brain natriuretic peptide (1-76)Peptide FragmentsCalcium Channel BlockersBiomarkersAnti-Arrhythmia Agents

Autor:innen und Institutionen

  • Department of Medical Research, Bærum Hospital, Vestre Viken Hospital Trust, Sogneprest Munthe-kaas vei 100, 1346 Gjettum, Norway.
  • Institute of Clinical Medicine, Faculty of Medicine, University of Oslo, Kirkeveien 166, 0450 Oslo, Norway.
  • Oslo Centre of Biostatistics and Epidemiology, Oslo University Hospital, Domus Medica Gaustad, Sognsvannsveien 9, 0372 Oslo, Norway.
  • Department of Cardiology, Drammen Hospital, Vestre Viken Hospital Trust, Dronninggata 28, 3004 Drammen, Norway.
  • ProCardio Center for Innovation, Department of Cardiology, Rikshospitalet, Oslo University Hospital, Sognsvannsveien 9, 0372 Oslo, Norway.
  • Department of Medicine, Ringerike Hospital, Vestre Viken Hospital Trust, Arnold Dybsjords vei 1, 3511 Hønefoss, Norway.

ORCID-Profile: Katrine Enge, Arnljot Tveit, Steve Enger, Are Hugo Pripp, Peter Selmer Rønningen, Magnar Gangås Solberg, Rune Byrkjeland, Kristoffer Andresen, Anders Halsen, Hanne Aaserud Aulie, Trude Steinsvik, Christian Hall, Sara Reinvik Ulimoen

Förderung

  • Southern and Eastern Norway Regional Health Authority
  • Vestre Viken Hospital Trust

Zitieren

APA

Enge, K., Tveit, A., Enger, S., Onarheim, S., Pripp, A. H., Rønningen, P. S., Solberg, M. G., Byrkjeland, R., Andresen, K., Halsen, A., Aulie, H. A., Steinsvik, T., Hall, C., & Ulimoen, S. R. (2024). Diltiazem reduces levels of NT-proBNP and improves symptoms compared with metoprolol in patients with permanent atrial fibrillation. European Heart Journal - Cardiovascular Pharmacotherapy. https://doi.org/10.1093/ehjcvp/pvae032

Vancouver

Enge K, Tveit A, Enger S, Onarheim S, Pripp AH, Rønningen PS, et al. Diltiazem reduces levels of NT-proBNP and improves symptoms compared with metoprolol in patients with permanent atrial fibrillation. European Heart Journal - Cardiovascular Pharmacotherapy. 2024. doi:10.1093/ehjcvp/pvae032

BibTeX
@article{Enge2024,
  author = {Enge, Katrine and Tveit, Arnljot and Enger, Steve and Onarheim, Sophia and Pripp, Are Hugo and Rønningen, Peter Selmer and Solberg, Magnar Gangås and Byrkjeland, Rune and Andresen, Kristoffer and Halsen, Anders and Aulie, Hanne Aaserud and Steinsvik, Trude and Hall, Christian and Ulimoen, Sara Reinvik},
  title = {Diltiazem reduces levels of NT-proBNP and improves symptoms compared with metoprolol in patients with permanent atrial fibrillation},
  journal = {European Heart Journal - Cardiovascular Pharmacotherapy},
  year = {2024},
  doi = {10.1093/ehjcvp/pvae032}
}
Kostenlos starten →